After establishing anti-tumor activity of muMAb 4D5/trastuzumab in the Fo2-1282 brain graft model, it was of interest to determine efficacy of T-DM1, an additional approved HER2-targeted therapeutic agent. Here, ERBB2 is linked to neoplasm.